Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
Diagnostic Microbiology and Infectious Disease
; : 115969, 2023.
Article
in English
| ScienceDirect | ID: covidwho-2311801
ABSTRACT
Patients undergoing hemodialysis (HD) are particularly vulnerable to coronavirus disease 2019 (COVID-19) and are at increased risk of developing severe infection. However, given the exclusion of such patients from clinical trials, there are limited data regarding the effectiveness of the antiviral drug nirmatrelvir/ritonavir (N/R) in patients on HD. We prescribed N/R to four patients on HD with COVID-19 after obtaining informed consent. Their clinical symptoms were improved at approximately 3 days after N/R administration. The viral load was reduced after approximately 10 days. The main adverse effects were nausea and vomiting. Rational dosage adjustment obtained good tolerance but did not influence the efficacy. These results suggest that N/R may be a promising agent for patients on HD with COVID-19.
Full text:
Available
Collection:
Databases of international organizations
Database:
ScienceDirect
Language:
English
Journal:
Diagnostic Microbiology and Infectious Disease
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS